---
document_datetime: 2026-02-24 14:30:06
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lenalidomide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lenalidomide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1947594
conversion_datetime: 2026-02-25 11:59:18.831427
docling_version:
  docling-serve: 1.13.1
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.2
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.4
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Lenalidomide Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                           |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 24/02/2026                          |                                             | Annex II                         | To update the RMP and Annex IID of the PI in line |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000317815   | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z (Type IB) - To update the RMP and Annex IID of the PI in line with the reference product Revlimid by removing the safety concern Tumor flare reaction (Follicular lymphoma and Mantle cell lymphoma indications) from Part II (Module VIII) and reclassifying Cardiac failure, Cardiac arrhythmias, and Ischaemic heart disease (including myocardial infarction) from important potential risks to important identified risks. Parts III, V, VI, and VII were updated accordingly.   | with the reference product Revlimid by removing the safety concern Tumor flare reaction (Follicular lymphoma and Mantle cell lymphoma indications) from Part II (Module VIII) and reclassifying Cardiac failure, Cardiac arrhythmias, and Ischaemic heart disease (including myocardial infarction) from important potential risks to important identified risks. Parts III, V, VI, and VII were updated accordingly.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|